# Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis

> **NCT03926026** · PHASE2 · COMPLETED · sponsor: **Nicox Ophthalmics, Inc.** · enrollment: 36 (actual)

## Conditions studied

- Blepharitis

## Interventions

- **DRUG:** Fluticasone Propionate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03926026
- **Lead sponsor:** Nicox Ophthalmics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-18
- **Primary completion:** 2019-10-21
- **Final completion:** 2019-10-21
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2023-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03926026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03926026, "Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03926026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*